Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haloperidol and Magnesium for Delirium Prevention
NCT06168773Phase 3Completed
- Sponsor
- Ain Shams University
- Start
- Nov 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in delirium comparing Haloperidol + Magnesium, Haloperidol and Placebo (3 arms). Primary endpoint: Incidence of delirium at 3 days. Started Nov 2022; status: completed.
02
Drugs
haloperidolmagnesium sulfate
03
Conditions
delirium
Beyond the preview
Go deeper on NCT06168773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06168773.